Abstract 38P
Background
Patients who reach pathological complete remission (PCR) after neoadjuvant therapy for triple-negative breast cancer (TNBC) have a better overall prognosis and do not require additional adjuvant therapy postoperatively according to current guidelines; however, some patients still have a lower survival rate.
Methods
We identified TNBC patients who completed neoadjuvant therapy and achieved PCR registered in the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. We analyzed the relationship between clinicopathological characteristics and overall survival, seeking to explore the high-risk factors for poor prognosis in patients who achieved PCR after neoadjuvant therapy for TNBC.
Results
A total of 1237 TNBC patients without distant metastases completed neoadjuvant therapy and achieved PCR, and their 5-year overall survival rate was 90.78%. We incorporated age, TNM stage (AJCC 7th edition), and presence of lymph node metastasis as variables to construct a multifactorial COX proportional risk model. The results found no statistically significant effect on survival time in stage II patients compared to stage I patients (HR=1.057, 95%CI 0.540-2.069, P=0.872), but statistically significant compared to stage III patients (HR=2.441, 95%CI 1.159-5.144, P=0.019). There was a statistically significant effect on survival time in patients with lymph node metastases compared to those without lymph node metastases (HR=1.913, 95%CI 1.253-2.921, P=0.003); and no statistically significant effect on survival time in patients younger than 40 years compared to those older than 40 years (HR=1.190, 95%CI 0.615-2.302, P= 0.605).
Conclusions
Younger age is not a factor influencing the prognosis of TNBC patients with PCR. For patients with stage III or lymph node metastases, even if PCR is achieved, further adjuvant therapy may be needed to improve prognosis. The type of adjuvant therapy to be used may need to be further confirmed by future prospective clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract